KRAS and non-small cell lung carcinoma: Co-mutation of STK11/LKB1 and KRAS was shown to downregulate PD-L1 expression level in NSCLC cell lines; in contrast, co-mutation of tp53 and KRAS was shown an upregulating effect [20, 21].